论文部分内容阅读
目的:探讨夏荔芪胶囊对良性前列腺增生(BPH)模型大鼠增殖细胞核抗原(PCNA)、半胱氨酸蛋白酶3(caspase-3)表达水平的影响。方法:50只雄性SD大鼠,随机分为5组,每组10只:空白组(假手术组),模型组,夏荔芪高、低剂量治疗组[1.20 g/(kg·d)、0.61 g/(kg·d)]及非那雄胺治疗组[0.8 mg/(kg·d)]。采用去势后皮下注射丙酸睾酮[0.5 mg/(kg·d),30 d],建立大鼠BPH模型。空白组及模型组予以生理盐水,治疗组予以相应药物,造模成功后连续灌胃30 d。实验结束后将各组大鼠于麻醉下留取双侧前列腺组织后处死,计算大鼠前列腺指数(前列腺湿重/体重);免疫组化法检测大鼠前列腺组织中PCNA的表达情况;免疫荧光法检测大鼠前列腺组织中caspase-3的表达水平。结果:与空白组相比,模型组的前列腺湿重(g)及前列腺指数(mg/g)明显增加(1 326±60 vs 471±17;2.89±0.18 vs 1.06±0.06,P均<0.01);与模型组比较,各治疗组的前列腺湿重及前列腺指数则明显降低,其中,夏荔芪高剂量组较低剂量组下降更明显(914±36 vs 1 099±46;2.02±0.08 vs 2.39±0.11,P均<0.01),而各治疗组中以非那雄胺组(817±53 vs 471±17;1.83±0.10 vs 1.06±0.06,P均<0.01)降低最明显。免疫组化结果显示,与空白组相比,模型组大鼠前列腺组织中PCNA表达明显增多,各治疗组与模型组相比,前列腺组织中PCNA表达均有明显减少,其中夏荔芪高剂量治疗组减少较为明显。免疫荧光结果显示,与空白组相比,模型组大鼠前列腺组织caspase-3表达量降低,各治疗组与模型组相比,前列腺组织中caspase-3表达明显增高,其中非那雄胺治疗组增高较为明显。结论:夏荔芪胶囊能明显降低BPH大鼠前列腺湿重及前列腺指数,通过降低前列腺组织中PCNA的表达水平,增高前列腺组织中caspase-3的表达,可能是其治疗BPH大鼠的机制。
Objective: To investigate the effect of Xiaqiqi capsule on the expression of PCNA and caspase-3 in benign prostatic hyperplasia (BPH) model rats. Methods: Fifty male Sprague-Dawley rats were randomly divided into five groups (10 rats in each group): 1.20 g / (kg · d) in the blank group (sham operation group), model group, 0.61 g / (kg · d)] and finasteride treatment group [0.8 mg / (kg · d)]. BPH model was established by subcutaneous injection of testosterone propionate [0.5 mg / (kg · d), 30 d] after castration. The rats in the blank group and the model group were given normal saline. The treatment group was given the corresponding drugs, and the rats in the treatment group were given gavage for 30 days after their success. At the end of the experiment, bilateral prostate tissues were removed from the rats under anesthesia, and the prostate index (wet weight / body weight of the prostate) was calculated. The expression of PCNA in the prostate tissue was detected by immunohistochemistry. Method to detect the expression of caspase-3 in rat prostate tissue. Results: Compared with the blank group, the wet weight (g) and the prostate index (mg / g) in the model group were significantly increased (P <0.01, P <0.01) ; Compared with the model group, the wet weight of the prostate and the prostate index of each treatment group were significantly decreased, of which, Xiali Qi high dose group decreased more significantly than the lower dose group (914 ± 36 vs 1 099 ± 46; 2.02 ± 0.08 vs 2.39 ± 0.11, P <0.01), while the decrease was most obvious in the finasteride group (817 ± 53 vs 471 ± 17; 1.83 ± 0.10 vs 1.06 ± 0.06, P <0.01). The results of immunohistochemistry showed that compared with the blank group, the expression of PCNA in the model group was significantly increased, and the expression of PCNA in the prostate tissue was significantly decreased in each treatment group compared with the model group. Among them, the high-dose XiaLiQi treatment Group reduction is more obvious. The result of immunofluorescence showed that compared with the blank group, the expression of caspase-3 in the model group decreased, the expression of caspase-3 in the prostate tissue was significantly higher in each treatment group than in the model group, and the finasteride treatment group Increased more obvious. Conclusion: Xiaqiqi Capsule can significantly reduce the prostate wet weight and prostate index in BPH rats, which may be the mechanism of BPH treatment by decreasing the expression of PCNA in prostate tissue and increasing the expression of caspase-3 in prostate tissue.